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Abstract: The power and influence of healthcare systems comes largely from the ability to prescribe
efficacious medicine. However, medicine can sometimes cause harm rather than bring benefits.
Systematically checking patients for the adverse effects of medicines, as listed in manufacturers’
literature, would protect patients from iatrogenic harm, but this is rarely undertaken. We argue
for the benefits of this approach using the example of the prescription of antipsychotics to
older adults. Prescribing antipsychotics to control challenging behaviours associated with dementia
is a controversial matter, and regulatory intervention is under discussion. Improved regulatory
systems could protect against iatrogenic harm, such as over-sedation, falls, tremor, or drug-induced
Parkinsonism. However, measuring the impact and outcomes of regulatory interventions has proved
difficult, not least because there are rarely systematic records of all adverse effects of medicines.
We indicate how regulatory initiatives to reduce antipsychotic prescribing can be supported by
systematic monitoring and documentation of patients’ signs and symptoms of putative adverse
drug reactions. Monitoring documentation then provides the rationale and support for professionals’
responses to identified problems. Longitudinal monitoring records would improve understanding of
the impact and outcomes of adverse drug reactions (ADRs) on health and wellbeing, and the many
costs of ADRs.
Keywords: adverse drug reactions; patient safety; nursing; medicine management; long-term care
1. Introduction
Improvements in population health in Western countries in the first half of the 20th century
were the culmination of several factors, including improved nutrition, public health measures,
and lifestyle changes [1], but gains since the 1940s are at least partly attributable to better
medicine [2,3]. Antimicrobial agents, starting with the sulphonamides, vaccination programmes,
and cardiovascular medicines, all contributed to significant reductions in mortality and morbidity [4–6].
Pharmaceutical advances transformed treatments in the mental health field, with antipsychotics
bringing significant benefits for illness management [7–9]. Unfortunately, these benefits have been
offset, to an uncertain degree, by new forms of iatrogenic disease associated with the adverse
effects of prescribed medicines [10,11]. Antipsychotics have not been exempt from adverse drug
reactions (ADRs), as considered in the present paper [12,13]. We reflect on the social context of
prescribing, the problem of preventable ADRs, our solution, and its congruence with the logic of
regulatory interventions.
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2. Power via Prescribing
The development of effective medicines did much to legitimise the cultural authority of the
medical profession, which exercised a professional monopoly over the prescribing of a wide range
of pharmaceuticals. Reflecting on the advances of the 1950s, Dr. Julian Tudor Hart explained that:
‘Doctors who were previously seen as people who could only write a prescription for some cough
medicine suddenly wrote a prescription for something that actually saved your life. The act of writing
the prescription wasn’t [SIC] any more skilled in the second instance than in the first, but the effect
was quite different. So doctors took a huge leap forward to becoming much, much more credible than
parsons and priests as emissaries of God [SIC]’ [14]. Even in an age of ‘patient-centred medicine’, medical
professionals remain socially distant from certain sections of the population, including people with mental
illness and older patients in long-term care institutions, who are the subject of this paper. Past studies
have found that medical care in nursing homes is suboptimal, with poor use of psychotropic medication
and shortcomings in pain management [15–17]. The near medical monopoly over prescribing means that
other members of the care team are rarely as attentive to the side effects of mental health medicines as
would be desirable. There is a risk that patients in care homes are disadvantaged by their ‘sick role’ status
and unintentional ‘othering’ [18], and risk being labelled by their diagnoses and prescriptions, without
adequate oversight of ongoing pharmacotherapeutic regimens. Ways need to be found to increase the
effectiveness of medicines’ monitoring by front-line care staff.
Healthcare professionals routinely underestimate harm and overestimate benefits of prescription
medicines [19]. Prescribed medicines benefit between 4% and 25% of patients [20], whilst ADRs affect
7.8% of primary care patients [21], 4.8–37% of people with cognitive impairment [22], and 11.0% of
hospitalised patients [23], killing 0.25% of hospitalised patients [24]. Lower figures (1.85%) are reported
in Norway, excluding events of unknown aetiology [25]. The inability to distinguish drug-induced
signs and symptoms from definitive medical diagnoses tends to result in further prescriptions,
increasing the risk of drug–drug and drug–disease interactions [26]. However, systematic processes to
check patients for the potential adverse effects of their medicines are rarely used [27,28] and consensus
for usage of available tools remains remote [29].
3. The Adverse Drug Reaction Problem
Preventable ADRs have proved an intractable problem over the last decade, causing 5–8% of
unplanned UK hospital admissions [30,31], rising to ~10% amongst older adults [32], and costing
the NHS £1 bn–£2.5 bn each year [33]. ADRs assessed as due to avoidable errors are responsible for
712–22,303 UK deaths, costing £98.5 m–£1.6 bn each year [34]. In Australia, 15% of admissions of
older people (aged 72–88 years) are due to ADRs, 92% of which are preventable [35], and admissions
related to all types of ADRs are associated with 28–32% longer hospital stays [36]. The problem is at
least as extensive in developing countries, at ~10% of admissions [37]. However, ~60% of adverse
drug events are not recognised and reported as such, which suggests that these figures may be
an underestimate [38], and higher figures (11%, 18% and 19.6% in the elderly), are quoted [21,39–41].
Most ADRs, adverse drug events (ADEs), and medicine mismanagement (including errors by
patients and professionals) are preventable [21,30,31], particularly with additional enhanced
monitoring [30,31,42–47], but comprehensive systematic multiprofessional approaches are needed
to address the problem [27,28] (Table S1).
4. Antipsychotics, Challenging Behaviour and Older Adults in Care Homes
Some 50% of residents in UK care homes are prescribed mental-health medicines [48]. Doses in
care homes [49] and primary care [16] are often excessive, and the proportion of care home residents
exposed to inappropriate medications ranges from 34% [50] to > 50% [51]. ADRs as a result of
mental-health medicines can be life-threatening (e.g., cardiac arrhythmias, cardiac hypofunction),
or debilitating (e.g., drug-induced Parkinsonism, ataxia, postural hypotension), or subtle, and mistaken
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for signs of ageing or underlying pathology. They can be overlooked, leading to behaviour problems,
xerostomia, constipation, poor food and/ or fluid intake, tremor, restlessness, sedation, pain, double
incontinence, or other problems, all causing potential loss of comfort and dignity [27,52].
The excess dose-related mortality and incidence of strokes associated with antipsychotics [53]
have long been concerns. In a trial of withdrawal of antipsychotics, 25/83 (30%) patients taking
antipsychotics and 48/82 (59%) taking placebos survived 36 months [54]. Between 1 in 8 and
1 in 29 people with dementia prescribed antipsychotics suffered a stroke [55]. Drug-induced
Parkinsonism occurred in 2–12% patients, and sedation in 15–24% [56]. A consensus is emerging
around overprescribing [16,50,51,57–60]. However, there is no consensus regarding the changes needed
to routine care [61–65], and reviewers indicate that evidence for single-profession interventions is
equivocal [66], of low quality [21,67], or uncertain [66,68–71]. The UK Department of Health’s National
Dementia Strategy [16], launched in 2009, and the Medicines and Healthcare products Regulatory
Agency (MHRA) recommendations [72], have not reduced antipsychotic prescribing in care homes [73],
and prescribing of atypical antipsychotics has increased across primary care [74], warranting a closer
review of regulatory interventions. Evidence collated for the recent Welsh Government (WG)
report [62] showed widespread concern about the continuing overuse of antipsychotics (Box 1).
During 2017 and 2018, the Health, Social Care and Sport Committee of the Welsh Government, chaired
by Dr D. Lloyd, collected evidence and made 11 recommendations to ‘protect some of our most vulnerable
citizens’. The report concludes: Antipsychotic medicines are being prescribed inappropriately, in many cases
as a first option rather than a last resort, to treat the behavioural and psychologic symptoms of dementia,
often without adequate reviews or records being kept p.61. Testimonies included:
“ . . . where you have somebody with behavioural or psychological problems relating to their
dementia, to routinely prescribe an antipsychotic medication without looking at what is underpinning
those behaviours and causing them is wrong, and it does seem to be the default position, which needs
to be addressed.” Alzheimer’s Society Cymru, p. 17.
“It is quite simply unacceptable that antipsychotic medication is still being used as a primary response to
‘challenging’ behaviour across many residential care services.” Older People’s commissioner, Wales, p. 17.
“I’d like to see the circumstance whereby people are not caught in this dreadful repeat prescription
mechanism, whereby it rolls on and on and on, and you could go for two years and nobody refers
to it. Some GPs, some practices, are better at reviewing than others. But, theoretically, because
you’re caught up in this repeat prescription mechanism, it could carry on and on and on. I’d like to
see—if you’re prescribed an antipsychotic and you have a diagnosis of dementia, there should be
a three-month mandatory review.” Care Forum Wales, p. 29.
Box 1. Use of Antipsychotics in Care Homes: A Report from the National Assembly for Wales.
What Should Be Done Differently?
Identification of medicine-related incidents as the most prevalent source of unsafe primary
care in Wales and England underlines the urgency of the problem [75]. Most ADRs, adverse drug
events (ADEs), or side-effects are due to poor monitoring, not poor prescribing [30,31,42–46], and are
dose-related [47].
The risk of iatrogenic harm could be addressed as an integral part of individual patient care.
Patients need to be systematically monitored or checked for the signs and symptoms of ‘undesirable’
effects as listed in manufacturers’ literature. To this end, we have developed a nurse-led approach
to medicines’ monitoring (Box 2). This multidisciplinary intervention is important to complement
regulatory initiatives in this area. Searches and reviews indicate there is no alternative comprehensive,
systematic patient assessment of problems potentially related to prescribed medicines [28,42,76,77].
We are unaware of a similar outcome-monitoring approach adopted in Norway or Australia [78];
a pharmacist-led de-prescribing education initiative in Australian care homes reduced antipsychotic
prescriptions, but not adverse outcomes [79].
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Our intervention, the Adverse Drug Reaction (ADRe) Profile asks nurses to systematically check patients for
the manifestation of itemised adverse side effects or undesirable effects of their mental health medicines,
as listed in the British National Formulary and manufacturers’ Summaries of Product Characteristics
(SmPCs), action problems identified, and share the Profile with pharmacists and/or prescribers. This is
a formalised and standardised approach to monitoring all patients prescribed mental health medicines,
regardless of diagnostic categories. The ADRe Profile comprises: vital signs, and changes in vital signs,
observations, focussed questions or reports of possible ADRs, prevention /health promotion areas likely
to be affected by medicines, including diet, medicine use, service user’s perspectives, and care plan
modifications (http://www.swansea.ac.uk/adre/requestforadretool/) (Figure 1). Nurses pass the completed
profile with problems highlighted to pharmacists and prescribers to inform medication review. The supporting
information suggests which medicines or conditions might be causing the indicated problems and what further
information might be of assistance (Figure 2). The list of problems is then juxtaposed with the medicines’ record,
and the multidisciplinary team determine possible aetiologies of problems identified, and whether medicines
need to be changed.
The ADRe Profile for mental health medicines was introduced to address nurses’ and patients’ concerns that
ADRs were neither recognised nor communicated to prescribers. The benefit of listing problems in one document,
which can be passed to prescribers reviewing medication, is that these problems then get addressed, doses
of antipsychotics and sedatives are reduced, and patients’ signs and symptoms resolve. Our trials provide
evidence that ADRe works [27,80], supported by other studies [81–84] (Table 1). ADRe and its supporting
information empower nurses by a democratisation and transfer of useful, necessary, and practical knowledge of
pharmacotherapeutics and medicine to nurses [85–87]; it was developed in Wales, a country with egalitarian
traditions [88].
Limitations of the ADRe Studies
Generalisation
ADRe was developed in post-industrial South West Wales. Findings from a small European country,
where most of the population are in an EU convergence zone (GDP < 75% of the EU mean), cannot necessarily
be extrapolated to different populations. Without further studies to confirm transferability, generalisation
of findings depends on logical inferences. However, medicine mismanagement is an international problem,
in urgent need of effective interventions [89].
Volunteer Bias
We acknowledge the potential for volunteer bias in all research designs. Only policy initiatives can determine
whether our findings will transfer to struggling organisations, as they are unlikely to volunteer for research
projects, and may be less likely to have sufficient staff to offer support to those withdrawing from medicines.
Participant recruitment to our studies was at the discretion of nurses, and we cannot discount the possibility of
selection bias.
Nurses’ Reporting
ADRe relies on nurses’ reports; some care home residents are non-verbal and some mental health service
users lack communication skills [84]. ADRe is vulnerable to nurses’ interpretations, and we acknowledge
that nurses may under-report patients’ ADRs [76]. Although ~50% of ADRe items can be identified in care
homes’ notes, the information takes ~1 h to retrieve [27], and prescribers are limited to 7–15 min per patient.
Therefore, ADRe increases the information passed to prescribers.
Time Needed to Complete ADRe
Initially, ADRe asks nurses or their assistants to do more work by spending 10–30 min documenting
problems with each patient, and acting on problems identified; we estimate this costs £20 [27], which can only
be compensated by reduction in patients’ demands following improved patient welfare. This initial barrier to
uptake usually recedes with familiarity and regular use. If problems are addressed, patients benefit, medicines
are optimised, and patients are calmer (Table 1); these clinical improvements persuade nurses to continue
with ADRe. The diversion of resources to ADR management may be cost-effective [77], but further work is
needed to explore any unintended consequences, such as neglect of other documentation.
Evaluating the Outcomes of ADRe
ADRe is comprehensive, with ~80 items, most of which are clinically important. Therefore, rather than
defining a single ‘outcome measure’, we have used a composite ‘number or problems identified and addressed’,
and described clinical gains. Table 1 has illustrative examples.
Box 2. The Adverse Drug Reaction (ADRe) Profile.
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Figure 1. An illustration of the Adverse Drug Reaction (ADRe) Profile for mental health medicines.
These are the first questions on the ADRe Profile. This is accompanied by a ‘How to Use’ sheet,
and supporting information (Figure 2). To request a copy of ADRe, visit: http://www.swansea.ac.uk/adre/.
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Figure 2. An example of ADRe’s Supporting Information. If a problem is identified, nurses are asked to
review the supporting information for that problem, and consider the actions suggested. The suggested
aetiologies should be discussed within the multidisciplinary team.
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Table 1. Studies on the ADRe Profiles.
Design Clinical Area Findings Case Reports, Examples of ADRs Addressedwithout Hospitalisation
Studies Using the ADRe Profiles
Jones et al. 2016 [81] ‘Before-and-after’ study of20 patients
Community mental health,
crisis resolution home treatment
The Profile identified previously unreported physical health
problems for all participants, including two previously
unreported potentially life-threatening problems
(cardiac arrhythmia, and valproate-induced pancreatitis). In all,
4 participants had medicines discontinued, 3 were referred to
consultant psychiatrists, 3 to general practitioners, 1 to ECG
technicians, and 1 to dentists. Previously neglected health
promotion issues were also recognised.
A middle-aged man, diagnosed with schizophrenia, had
previously unrecorded but potentially serious cardiovascular
problems (cardiac arrhythmia, intermittent acute chest pain) that
worsened with exertion and radiated. He was referred
immediately to his GP. The consultant determined that this case,
and one other, fulfilled the criteria for a serious ADR, as it would
have resulted in hospitalisation if unattended.
Jordan et al. 2015 [27]
Stepped wedge randomised
controlled trial (RCT) over
7 months, 5 homes,
41 participants, 125 record
reviews before Profile
implementation and
124 after
Care home residents with
permanent
cognitive impairment
Profile administration increased the number of problems
addressed from a mean of 6.02 [SD 2.92] to 9.86 [4.48], effect size
3.84, 95% CI 2.57–4.11, p < 0.001. For example, pain was more
likely to be treated (adjusted Odds Ratio (aOR) 3.84, 1.78–8.30),
and more patients attended dentists and opticians (aOR 52.76
(11.80–235.90) and 5.12 (1.45–18.03), respectively). Profile use was
associated with reduction in mental health medicines (aOR 4.45,
1.15–17.22).
A lady in her late 80s, diagnosed with dementia at first
administration of the Profile, was noted to be aggressive, restless,
confused, sedated, and agitated. The ADRe Profile helped staff
identify that hyoscine might be the cause.
Hyoscine was discontinued. By the end of the study, 5 months
later, aggression, restlessness, and sedation were no
longer problems.
Jordan et al. 2014 [82]
Feasibility study, 11 patients’
records reviewed 3 times
(before Profile
implementation, after,
and 3 months later),
3 homes.
Feedback from clinicians
Care home residents with
permanent
cognitive impairment
The Profile took 20–25 min to implement, caused no harm,
and supplemented usual care. On first use, the Profile identified
previously undocumented problems for all service users: mean
12.7 [SD 4.7]. One month later, a mean of 4.9 [3.6] problems had
been ameliorated. Clinical gains documented included: new
prescriptions to manage pain (2 participants), psoriasis (1),
Parkinsonian symptoms (1), rash (1); dose reduction of
benzodiazepines for one service user; new care plans for oral
hygiene, skin problems, and constipation.
A lady in her mid-60s, diagnosed with ‘Korsakoff’s syndrome’
and psoriasis, was noted to be oversedated. Benzodiazepine and
antipsychotic prescribing were reduced, and sedation was no
longer a problem at follow up. Itching rashes were also identified,
more creams were administered, including an ‘as needed’
prescription for hydrocortisone, and symptoms were ameliorated.
Gabe et al. 2014 [80]
Parallel group RCT
Researcher observed clinical
visits before and after
implementation of the
Profile in the
intervention arm.
Feedback from patients
and clinicians
Respiratory medicine,
outpatient department,
54 patients recruited and
followed up
The increase in numbers of problems per participant identified at
follow up was significantly higher in the intervention arm where
the median change was +20.5 (inter-quartile range (IQR) 13–26)
while that in the control arm was −1 (−3 to +2) (Mann–Whitney
U test: z = 6.28, p < 0.001). The increase in numbers of actions per
participant taken at follow up was significantly higher in the
intervention arm, where the median increase was +2.5 (1–4),
while that in the control arm was 0 (−1.75 to +1) (Mann–Whitney
U test: z = 4.40, p < 0.001).
Without the Profile, no actions were taken by nurses for a lady in
her 50s, with respiratory problems sufficiently severe as to
warrant oral prednisolone. Using the Profile, nurses advised her
to contact her GP to seek advice regarding mood swings,
depression, headaches, and immunisations. The nurse
commented: “I would not have picked up on x’s depression
without the Profile”.
Gabe & Jordan 2014 [83]
Inter-rater reliability Profiles
completed in the presence of
an observer
Respiratory medicine,
outpatient department,
48 patients prescribed
respiratory medicines
Cohen’s κ for inter-rater reliability for each item ranged 0.73–1
(good to complete agreement). The Profile identified previously
unsuspected problems in all participants, including muscular
weakness, skin, and mouth problems.
A lady in her 70s prescribed corticosteroids, bronchodilators,
and other respiratory medicines, reported multiple oral problems,
plus losing two stone in weight over the last six months, because
her mouth was too sore to eat comfortably. She was advised to
rinse her mouth shortly after each inhaler use, seek advice from
the nurse for information on inhaler technique, and maintain
routine dental check-ups.
Jordan et al. 2004 [76]
Comparison of instruments
available to monitor
antipsychotic medicines.
Inter-rater reliability,
20 Profiles completed in the
presence of an observer
Community mental health
teams, 20 service users
prescribed long-term medicines
The ADRe Profile assessed a broader range of physiological
parameters and potential problems than other instruments. It is
the only instrument with supporting information to prompt
action in routine care.
Items on the Profile had moderate-to-complete inter-rater
reliability (ranging 0.44–1.00)
NA
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Table 1. Cont.
Design Clinical Area Findings Case Reports, Examples of ADRs Addressedwithout Hospitalisation
Jordan et al. 2002 [84]
‘Before-and-after’ study
with 1 intervention and
1 comparator group
3 community mental health
teams in post-industrial South
Wales, 40 service users
prescribed long-term mental
health medicines
Amongst the 20 clients in the intervention group, the Profile
highlighted several problems, two of which were urgent. In the
intervention group, the mean number of problems actioned per
client increased from 0.35 (range = 0–4) without the Profile to 3
(range = 0–6) with (z = −3.747, 2 tailed p < 0.001). Nurses offered
appropriate advice or encouraged clients to contact the relevant
agencies to resolve the physical health problems identified. In the
comparator group, the number of problems actioned declined
from 0.85 (0–3) to 0.5 (0–2), a statistically insignificant difference
(z = –1.47, p = 0.14).
Of 20 clients in the intervention group:
• One had coupled beats, and was urgently referred to the
prescriber, who immediately reduced the dose of the
antipsychotic depot.
• One had severe hypertension, 200/120 mmHg, and was
immediately referred to his general practitioner (GP),
and subsequently to renal physicians.
• Two had postural hypotension. They were encouraged to
maintain adequate fluid intake. Notes were attached to the
medical notes to alert the psychiatrist.
• Six had a degree of hypertension, above 140/90 mmHg.
Measurements were repeated at three subsequent
clinic visits. Five clients were advised to contact their GPs,
one refused. The 6th client was being investigated for
a cerebral tumour.
• Inflation of the cuff revealed marks of intravenous injections
on the forearm of one client. There were no previous records
of substance misuse..
Jordan 2002 [85]
‘Before-and-after’ study
with intervention and
comparator groups,
40 patients.
Interviews with
professionals and
service users
Community mental health
teams in post-industrial
South Wales
Profiles apportioned aspects of medication management between
nurses and medical prescribers. Most actions taken by nurses to
alleviate adverse effects concerned clients’ physical health and
advice on health-promotion. Nurses’ interventions would have
been more effective had they been able to supply clients with
certain medicines, for example for sunblock or oral care.
For some clients, ameliorating the adverse effects of medication
would have involved changes to prescribed antipsychotic
medication; here, decisions were more equivocal.
One client was referred to his GP with chest pain; since he was
receiving 100mg fluphenazine decanoate per week, the absence of
an ECG recording contravened current guidelines.
Nurse: You can attach this to the notes. Show the psychiatrist
a copy. If you took the time to take it to the psychiatrist—it
could work. (...) By using this we’ll have more evidence to show
that there are side effects and we’re concerned, to get
medication reviewed. Outpatient appointments are very ‘in and
out’ and things get missed.
Studies undertaken before the Profile was introduced
Jordan et al. 2000 [86] Stakeholder interviews and3 service user focus groups
Mental health nursing: 7 service
user representatives, 3 service
user focus groups
Service users described serious shortfalls in professionals’
abilities to inform them of common adverse effects of medication;
these problems were attributable to inadequate
educational preparation.
User group representative: CPNs (Community Psychiatric
Nurses) focus on the psychiatric illness, they don’t see the
medical side, or want to become involved. It’s to do with
their training. They wouldn’t help with the constipation or the
sunburn for my daughter. This should be in their training.
Jordan et al. 1999 [87]
Interviews, observations,
and questionnaires with
14 community mental
health nurses.
Community mental
health teams
Service users were experiencing ADRs, but nurses did not have
a structure to record and report problems. Doctors were seeking
information from nurses, rather than directly from service users.
Nurse: There should be a form of structure for it
(client education). It’s down to individuals whether or not they
see the importance of educating people regarding their
medication, and I think that should be part and parcel of
the assessment. I think it should be there, and I know that it’s not,
from my own experience. To me, whoever is on medication, I will
ask them if they understand their medication. People say
“Oh well, that’s the GP’s role, that’s the doctor’s role”, but it isn’t.
It isn’t done and I always ask them that question, “Do you
understand what your medication’s doing?”, and I suppose my
knowledge maybe isn’t enough either, and I think that maybe I
need more training to carry that further. (...) We’ve got to be
prepared to answer questions—informed answers have got to be
given, then people will ask, ‘What’s this for, what’s this supposed
to do to me?’ (...)
ADRe was formerly known as the West Wales ADR Profile.
Pharmacy 2018, 6, 102 9 of 19
5. Regulatory Interventions to Modify Prescribing and Outcomes
It remains to be seen how regulatory interventions will address the problems outlined and be
placed in the public domain. However, there are no guarantees that regulatory interventions will
improve the processes and outcomes of care, and structures are needed to pre-empt regulatory failure.
Our logic model outlines the process of change—actions, beliefs, processes and outcomes—and possible
unintended consequences (Figure 3).
Figure 3. Logic Model for the introduction of regulation to reduce prescribing of antipsychotics
to older adults. Real-world changes may follow a logic model of resources/actions/process
change/outcome change (The Kellogg Foundation 1998). In any mandated intervention, there is
an opportunity cost, and each phase may be associated with unintended consequences.
5.1. Actions
While some regulatory actions are as straightforward as product withdrawal, many restrictions are
complex, and therefore more difficult to target and monitor. For example, while prescribers are advised
to restrict doses of paracetamol for people weighing <60 kg, and restrict further for those <50 kg [90],
medicines are often prescribed without knowing patients’ current weight. Unless information on
weight is passed to the prescriber, using ADRe or similar documentation, ascertaining such detail may
be time-consuming, which results either in the restriction being overlooked or in the product falling
out of favour. Many cautions and contraindications apply to subgroups; however, patients move
between categories by aging, developing cardiovascular risk factors, or becoming pregnant. There is
little indication that pre-emptive surveillance is widely undertaken, particularly in preconception
care [91]. If de-prescribing is incongruent with prior beliefs of clinician or patient, change may be
resisted and difficult [92]. Where regular monitoring is mandated, products may fall out of favour if
the monitoring is thought to be too onerous (see ‘switching’, below).
5.2. Change in Belief
Patients’ attitudes and commitments to their therapeutic regimen may influence prescribing:
For example, a time series analysis found that admonitions had no impact on prescribing of opioids,
intimating that patient preference or dependence may be influential [93]. Prescribers’ degree of belief
in new evidence or interventions will determine transfer of evidence to individual patients, as is
recognised by advocates of evidence-based medicine: research evidence can inform, but can never
replace individual clinical expertise, and it is this expertise that decides whether the external evidence
applies to the individual patient, and if so, how it should be integrated into a decision ([94], p. 72).
The risks of unmedicated illness may override the risks of ADRs: for example, the prescription of
antiepileptics was unaffected by warnings of suicidality [95]. Consultant psychiatrists responsible for
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clients with histories of severe mental illness, sometimes including homicides, are reluctant to change
therapeutic regimens, despite disabling ADRs [84]. Systematic completion of a standard instrument
like the ADRe Profile offers prescribers a record of all drug-related harms and symptoms of mental
illness, such as irritability and hallucinations, and physical illness, such as chest pain and dyspnoea,
to assist decision-making.
Learning and Unintended Learning
While regulation is directed at prescribing, there may be unintended impacts on
other behaviours. Warnings of the impact of leukotriene receptor antagonists on mood and behaviour
(aggression/hostility) increased prescriber and patient awareness, resulting in a rise in mental health
contacts from 8.32 to 8.93%/month in adults, and suicide attempts from 0.06 to 0.09% in those aged
18–29 [96]. Spontaneous reporting overlooks ~95% of ADRs [97], leaving the data vulnerable to bias.
Regulatory warnings increase spontaneous reporting, intensifying respondent and notoriety biases.
For example, osteonecrosis of the jaw in 81 patients co-exposed to bisphosphonates and chemotherapy
and/or corticosteroids was attributed solely to bisphosphonates [98]. In the French pharmacovigilance
database, reports of adverse events rose in the 2 years following warnings; for example, reports
of rhabdomyolysis more than doubled after this issue was highlighted in 2001 [99]. Increases in
spontaneous reporting may reflect healthcare professionals’ learning, rather than real increases in
ADRs [98,99]. ADRe depends on regular, routine monitoring, rather than spontaneous reports.
5.3. Processes of Care
Prescribers’ and service users’ degree of belief, learning, and commitment to therapeutic
intervention influence process measures, such as changes in prescribing, checking patients for
restrictions, and engaging in close monitoring. Changes are contextualised by prior beliefs, entrenched
attitudes, and perceptions of what is considered feasible and achievable [100].
Unintended Processes
Both service users and professionals may ‘work round’ restrictions or mandated monitoring.
Where medicines are restricted or restrictions are seen to be inconvenient, patients may turn to
buying over the internet. Alternative remedies may be sought from herbalists, suppliers of other
complementary medicines, or even suppliers of recreational drugs. Anecdotally, where prescribers
refuse to supply procyclidine to users of antipsychotic medicines, service users purchase this from street
dealers or resort to feigning the signs of dystonia to prompt nurses to administer procyclidine under
PRN (pro re nata or as needed) prescriptions. The UK’s Quality Outcomes Framework (QOF) aimed to
link general practitioners’ (GPs) pay to quality of care [101]. This was expanded in 2006 to include
completion of a questionnaire assessment of symptoms of depression, aimed at targeting prescribing
to those more severely depressed [102]. However, this requirement for additional documentation was
circumvented by using symptom rather than diagnostic codes [103].
Regulation may promote therapeutic substitution or switching. Additional regulatory requirements
may encourage switching to (more expensive) medicines where patient monitoring is not mandated.
For example, the prescription of factor Xa inhibitors increased between 2010 and 2014 [104], due, in part,
to the reduced need to attend anticoagulation clinics [105]. Substitution of diclofenac for coxibs increased
the use of diclofenac, until the recognition of the dose–response association of this medicine with
cardiovascular events [106], and subsequent withdrawal from pharmacy sale [107].
Switching may not be problem-free. In the USA, guidelines to reduce prescribing of antipsychotics
for older adults resulted in increased prescribing of benzodiazepines (adjusted Odds Ratio (aOR) 3.05,
1.17–7.94) and anti-dementia medicines (aOR 1.98, 1.12–3.50), but little change in use of antipsychotics
(aOR 0.83, 0.37–1.89) (n = 331) [108]. ADRe aims to be comprehensive, capturing the undesirable effects
of sedatives and other medicines, so it continues to be useful after therapeutic substitution to assess
change or the emergence of different adverse effects.
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5.4. Outcomes of Care
Changes to the processes of care do not necessarily improve outcomes. Outcomes, particularly
mortality, are heavily confounded by lifestyle and genetic factors. Implementation of the UK’s QOF,
associated with large monetary incentives, did not significantly improve mortality [109].
More comprehensive data are needed to capture all consequences of prescribing and regulatory
change to minimise risk. Approximately 50% of mundane problems, such as constipation, xerostomia,
dizziness, and incontinence, which may be drug-related, remain incompletely documented, reducing
the likelihood of identifying both harms and benefits, unintended and intended, in practice and in
pharmacovigilance database work [110]. Most ADRs are not medically serious, but these mundane
problems, from incontinence to xerostomia, negatively impact quality of life or adherence to therapeutic
regimens. Such problems are not medically interesting (an inverse interest law), and are only captured
by proper surveillance. Direct questioning by professionals doubles the number of adverse drug
events identified [111]. Primary care pharmacist questioning identified problems in 168/180 patients,
for example, xerostomia, sweating, diarrhoea, constipation [112]. ADR reporting in clinical trials
using standard questions and diary cards increased ADR reporting, for example, from 1.5–5.1%
to 29–49% [113]. In USA primary care, 18% (394/2248) of patients reported ADRs to researchers,
but only 3% (64) had previously had these documented [114]; incontinence and headache are among
problems least likely to be documented [115]. When considered together, the diverse pharmacist-led
medication therapy management programmes improve medication appropriateness, adherence,
and dosages, but there is little evidence for their effectiveness in identifying and resolving drug
therapy problems [71]. Nurse-led direct questioning using ADRe increased the mean number of
problems recorded from 7.30 [SD 3.18] per participant to 15.81 [SD 5.90], and outcomes such as pain
and falls improved [27]. The ADRe Profile addressed serious ADRs in ~10% patients in mental health
teams [81,84], and in care homes [27,82].
Unintended Outcomes
The diagnostic uncertainty and social contingency inherent in recognition of unintended
consequences suggest the need for more comprehensive, targeted data collection.
Uncertainties surrounding complex restrictions are compounded by social and geographical distance
between prescriber and patient, patients’ and professionals’ expectations (the Rosenthal effect),
the mundane nature of many ADRs, and confounding by indication, co-prescription,
or socioeconomic status. These impact on patients’ opportunities to report problems, the number
and nature of problems recorded, and availability of data. Recognition is particularly difficult where
outcomes are transgenerational, beyond the immediate neonatal period (education), or in vulnerable
subgroups (e.g., co-exposed, polymedicated, immunosuppressed, or genetically vulnerable).
Where medicines are changed or discontinued, unmedicated illness may emerge. The concerns
regarding valproate increased prescribing of lamotrigine in pregnancy. However, enzyme induction
in pregnancy demands dose adjustments; where these were not made, nine maternal deaths
resulted [116]. A cluster randomised controlled trial (RCT) involving people with dementia in care
homes (n = 177) found that a pharmacist review of antipsychotic medication reduced antipsychotic
prescribing and led to a non-significant reduction in mortality (28% vs. 35%), but a worsening of
neuropsychiatric symptoms [117] and quality of life measures, particularly negative emotions [118].
However, this unintended consequence of guideline compliance might be confined to the most
disturbed, and withdrawal reduces the risk of falls [119]. By capturing all possible problems at
regular intervals, ADRe promotes early recognition and reporting and improves our understanding of
impact and outcomes.
One unintended outcome of regulatory interventions is to accentuate health inequalities.
Prescription of antipsychotics [74], selective serotonin re-uptake inhibitors (SSRIs) in pregnancy [120],
and polypharmacy (>9 medicines) are concentrated amongst more deprived socioeconomic groups [121],
leading to concerns that ADRs are contributing to health inequalities [122]. UK primary care is
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characterised by the Inverse Care Law [123], whereby resources are diverted away from areas of social
deprivation and the greatest medical need. GPs in the most deprived areas are responsible for more
patients and are under greater pressures and risk of burnout [124]. Working under such conditions may
prove a barrier to implementation of regulations or warnings: Checks or new restrictions for medicinal
products may be overlooked due to the urgency of care. The resources to monitor patients during
withdrawal of medication may simply not be there, allowing outdated and suboptimal practices to persist.
Therefore, to ensure that the most disadvantaged patients benefit, interventions need to be mandated and
inspected. Accordingly, the Welsh Government has asked the Care Homes’ Inspectorate to check quarterly
medication reviews of antipsychotic prescribing in care homes [62]. Were ADRe to be routinely utilised in
this task, it would bring rigour and substance to these reviews. Its person-centred documentation of signs
and symptoms will prevent this regulatory intervention being reduced to an audit of medicines’ charts.
6. Conclusions
The reluctance to de-prescribe is based, in part, on the potential risks of medication withdrawal,
and the associated commitment of resources, but perpetuates the ‘othering’ [18] and control of
service users. For some medicines, ADRs are overtly stigmatising and disempowering—such as
the agitation, nervousness, and anxiety caused by some antidepressants, and the movement disorders
and cognitive impairment caused by antipsychotics. It is incumbent on healthcare professionals to
‘do no harm’, but the over-reliance on prescriptions can lead to real harm and an imbalance of power.
Regulation at system level alone is not enough: Oversight should include comprehensive patient
checks for undesirable adverse effects of medicines, however mundane. The ADRe Profile provides
a sensible and usable tool to achieve improved patient care and increased understanding of the impact
of ADRs.
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